Table 2.

Univariate analysis of overall survival (OS) and disease-free survival (DFS) with prognostic factors of HCC.

Variables	Univariate Analysis
	OS			DFS
	HR	95% CI	p-Value	HR	95% CI	p-Value
Sex (male vs. female)	0.89	0.60–1.33	0.57	0.93	0.68–1.28	0.66
Age (≤66 vs. >66)	1.16	0.80–1.66	0.43	0.93	0.70–1.22	0.59
HBV infection (yes or no)	1.09	0.68–1.75	0.72	1.02	0.71–1.48	0.91
HCV infection (yes or no)	1.35	0.94–1.94	0.099	1.23	0.93–1.62	0.14
No infection (yes or no)	0.66	0.43–1.01	0.056	0.83	0.60–1.13	0.23
Child Pugh grade (B or C vs. A)	1.96	1.08–3.55	0.027	1.58	0.93–2.67	0.09
AFP (≤20 vs. >20 ng/mL)	2.35	1.64–3.89	<0.001	1.68	1.28–2.21	<0.001
PIVKA-II (<40 vs. ≥40 mAU/mL)	1.42	0.93–2.17	0.11	1.30	0.94–1.79	0.11
CEA (≤5 vs. >5 ng/mL)	0.81	0.36–1.85	0.62	0.84	0.47–1.50	0.55
CA19-9 (≤37 vs. >37 U/mL)	1.20	0.61–2.37	0.6	0.87	0.48–1.56	0.64
Tumor size (≤5 vs. >5 cm)	1.45	1.01–2.10	0.047	1.42	1.06–1.91	0.018
Tumor number (multiple vs. single)	2.14	1.46–3.14	<0.001	2.39	1.75–3.26	<0.001
Differentiation (mod/por vs. wel)	1.57	1.01–2.43	0.043	1.48	1.06–2.07	0.021
Hepatic vein invasion (yes vs. no)	2.36	1.56–3.55	<0.001	2.40	1.70–3.37	<0.001
Portal vein invasion (yes vs. no)	2.13	1.48–3.08	<0.001	1.93	1.43–2.60	<0.001
Tumor category (T3–4 vs. 1–2)	3.00	2.12–4.25	<0.001	2.44	1.85–3.22	<0.001
Fibrosis stage (4 vs. 0–3)	1.59	1.12–2.26	0.0099	1.61	1.23–2.12	<0.001
Activity stage (2–3 vs. 0–1)	1.01	0.69–1.48	0.95	1.18	0.88–1.54	0.27
TNM stage (III–IV vs. I–II)	2.97	2.09–4.22	<0.001	2.57	1.95–3.39	<0.001
LSD1 (positive vs. negative)	2.16	1.31–3.56	0.0024	1.75	1.24–2.48	0.0016